|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 237.80 EUR | +1.23% |
|
-0.50% | -0.29% |
| 05-19 | UCB's Bimzelk demonstrates superior efficacy over Skyrizi (risankizumab) in psoriatic arthritis | RE |
| 05-12 | H Lundbeck raises 2026 forecasts on US demand, delayed generic competition | RE |
| Capitalization | 44.72B 51.84B 40.96B 38.71B 71.36B 5,019B 73.15B 488B 190B 2,363B 195B 190B 8,251B | P/E ratio 2026 * |
25.5x | P/E ratio 2027 * | 19.6x |
|---|---|---|---|---|---|
| Enterprise value | 43.23B 50.12B 39.6B 37.42B 68.98B 4,852B 70.72B 472B 184B 2,284B 188B 184B 7,977B | EV / Sales 2026 * |
5.11x | EV / Sales 2027 * | 4.33x |
| Free-Float |
61.59% | Yield 2026 * |
0.62% | Yield 2027 * | 0.64% |
Last Transcript: UCB
Trading UCB
| 1 day | +1.28% | ||
| 1 week | -0.50% | ||
| Current month | +2.90% | ||
| 1 month | -8.15% | ||
| 3 months | -13.84% | ||
| 6 months | +3.61% | ||
| Current year | -0.29% |
| 1 week | 228.7 |  | 241.1 |
| 1 month | 223 | | 259 |
| Current year | 223 | | 289.5 |
| 1 year | 152.95 | | 289.5 |
| 3 years | 65.4 | | 289.5 |
| 5 years | 65.4 | | 289.5 |
| 10 years | 54.84 | | 289.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 01/01/2015 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 59 | 01/07/2020 |
Alistair Henry
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/05/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 01/01/2012 | |
| Director/Board Member | 67 | 01/01/2015 | |
| Director/Board Member | 56 | 24/04/2014 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +4.91% | 0.42% | 27 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.23% | -0.50% | +47.67% | +172.51% | 51.84B | |
| +0.10% | -12.87% | +5.66% | -16.96% | 64.13B | |
| -2.89% | +34.60% | +34.60% | +34.60% | 41.28B | |
| -0.22% | -0.32% | -59.65% | -67.95% | 33.94B | |
| -0.70% | -4.41% | +47.22% | -38.23% | 28.13B | |
| -4.97% | -14.17% | +73.25% | -63.78% | 18.14B | |
| +0.43% | -3.56% | +49.82% | +50.39% | 19.1B | |
| -0.75% | -8.79% | +43.58% | +104.38% | 17.72B | |
| +0.25% | -0.55% | +40.53% | +82.66% | 15.96B | |
| +1.04% | +0.08% | +95.90% | +381.05% | 12.93B | |
| Average | -0.15% | -5.29% | +37.86% | +63.87% | 30.32B | |
| Weighted average by Cap. | -0.20% | -5.89% | +28.05% | +45.52% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.46B 9.81B 7.75B 7.32B 13.5B 949B 13.84B 92.32B 35.95B 447B 36.8B 36.01B 1,561B | 9.53B 11.05B 8.73B 8.25B 15.21B 1,070B 15.59B 104B 40.52B 504B 41.47B 40.59B 1,759B |
| Net income | 1.76B 2.04B 1.61B 1.53B 2.81B 198B 2.88B 19.24B 7.49B 93.15B 7.67B 7.51B 325B | 2.26B 2.63B 2.07B 1.96B 3.61B 254B 3.71B 24.72B 9.63B 120B 9.85B 9.64B 418B |
| Net Debt | -1.49B -1.72B -1.36B -1.29B -2.37B -167B -2.43B -16.23B -6.32B -78.57B -6.47B -6.33B -274B | -3.43B -3.97B -3.14B -2.96B -5.47B -384B -5.6B -37.39B -14.56B -181B -14.9B -14.59B -632B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/05/26 | 237.80 € | +1.23% | 35,897 |
| 19/05/26 | 234.90 € | +2.17% | 271,822 |
| 18/05/26 | 229.90 € | -3.00% | 235,494 |
| 15/05/26 | 237.00 € | -1.37% | 151,927 |
| 14/05/26 | 240.30 € | +0.50% | 108,633 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- UCB Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition